Vir Biotechnology, Inc. VIR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$29K-100% | $64.07M+26,596% | $240K-80.2% | $1.21M-60.0% | $3.03M-75.5% | ||
| —— | —— | —— | $1.2M-60.3% | $3.03M-74.1% | ||
| $108.92M+23.3% | $88.35M-41.7% | $151.46M+55.3% | $97.51M-17.8% | $118.65M+11.8% | ||
| $23.34M-1.2% | $23.62M+6.2% | $22.23M-0.2% | $22.28M-6.9% | $23.94M-10.3% | ||
| $132.26M+18.1% | $111.99M-35.5% | $173.68M+45.2% | $119.63M-16.1% | $142.58M+10.1% | ||
| -$132.29M-176% | -$47.92M+72.4% | -$173.44M-46.5% | -$118.42M+15.1% | -$139.55M-19.1% | ||
| 456,172.4%+456,247pp | -74.8%+72,193pp | -72,267.9%-62,514pp | -9,754.3%-5,152pp | -4,602.5%-3,656pp | ||
| $7.19M-7.9% | $7.8M-16.7% | $9.36M-13.2% | $10.79M-12.2% | $12.29M-13.2% | ||
| $6.77M+39.2% | $4.86M-53.6% | $10.47M+37.2% | $7.63M-59.0% | $18.6M+49.1% | ||
| -$125.53M-192% | -$43.06M+73.6% | -$162.97M-47.1% | -$110.79M+8.4% | -$120.95M-15.5% | ||
| $170K— | —— | $168K-1.2% | $170K+963% | $16K+119% | ||
| -$125.7M-193% | -$42.92M+73.7% | -$163.14M-47.0% | -$110.96M+8.3% | -$120.97M-15.7% | ||
| 433,431%+433,498pp | -67%+67,908pp | -67,975.4%-58,836pp | -9,139.9%-5,150pp | -3,989.6%-3,144pp | ||
| -$0.85-183% | -$0.30+74.4% | -$1.17-46.2% | -$0.80+9.1% | -$0.88-15.8% | ||
| -$0.85-183% | -$0.30+74.4% | -$1.17-46.2% | -$0.80+9.1% | -$0.88-15.8% | ||
| 147.4M+6.4% | 138.5M-0.3% | 138.9M+0.3% | 138.4M+0.7% | 137.5M+0.9% | ||
| 147.4M+6.4% | 138.5M-0.3% | 138.9M+0.3% | 138.4M+0.7% | 137.5M+0.9% | ||
| -$170K— | —— | $1.34M+139% | -$3.38M-153% | $6.38M+645% | ||
| -$254K+24.2% | -$335K-46.9% | -$228K-201% | $226K+414% | -$72K+85.8% | ||
| $0— | $0— | $0+100% | -$172K-1,620% | -$10K— | ||
| -$132.29M-176% | -$47.92M+72.4% | -$173.44M-46.5% | -$118.42M+15.1% | -$139.55M-19.1% | ||
| -$129.48M-188% | -$45.02M+73.6% | -$170.45M-47.6% | -$115.5M+15.5% | -$136.68M-19.6% | ||
| -$129.48M-188% | -$45.02M+73.6% | -$170.45M-47.6% | -$115.5M+15.5% | -$136.68M-19.6% | ||
| 446,479.3%+446,550pp | -70.3%+70,948pp | -71,018.8%-61,505pp | -9,514%-5,006pp | -4,507.9%-3,584pp | ||
| -$132.29M-176% | -$47.92M+72.4% | -$173.44M-46.5% | -$118.42M+15.1% | -$139.55M-19.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Vir Biotechnology, Inc.'s revenue?
- Vir Biotechnology, Inc. (VIR) generated $65.5M in revenue over the trailing twelve months, up 214.0% year over year.
- Is Vir Biotechnology, Inc. profitable?
- Vir Biotechnology, Inc. is not currently profitable: it reported a net loss of $442.7M over the trailing twelve months, a -676.0% net margin.
- What are Vir Biotechnology, Inc.'s profit margins?
- Gross margin is 96.1% and operating margin is -720.8%, with a -676.0% net margin.
- What is Vir Biotechnology, Inc.'s earnings per share?
- Vir Biotechnology, Inc.'s diluted EPS over the trailing twelve months is $-3.12.
- Where does Vir Biotechnology, Inc.'s income statement data come from?
- Every line is extracted from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
